MDT

95.45

+0.23%↑

VEEV

282.68

-3.65%↓

A

141.14

-0.55%↓

HQY

91.44

+0.52%↑

TLRY

1.53

-1.29%↓

MDT

95.45

+0.23%↑

VEEV

282.68

-3.65%↓

A

141.14

-0.55%↓

HQY

91.44

+0.52%↑

TLRY

1.53

-1.29%↓

MDT

95.45

+0.23%↑

VEEV

282.68

-3.65%↓

A

141.14

-0.55%↓

HQY

91.44

+0.52%↑

TLRY

1.53

-1.29%↓

MDT

95.45

+0.23%↑

VEEV

282.68

-3.65%↓

A

141.14

-0.55%↓

HQY

91.44

+0.52%↑

TLRY

1.53

-1.29%↓

MDT

95.45

+0.23%↑

VEEV

282.68

-3.65%↓

A

141.14

-0.55%↓

HQY

91.44

+0.52%↑

TLRY

1.53

-1.29%↓

Search

Iovance Biotherapeutics Inc

Open

SectorHealthcare

2.14 -3.17

Overview

Share price change

24h

Current

Min

2.14

Max

2.27

Key metrics

By Trading Economics

Income

4.5M

-112M

Sales

11M

60M

Profit margin

-186.246

Employees

838

EBITDA

8.3M

-102M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+462.5% upside

Dividends

By Dow Jones

Next Earnings

6 Nov 2025

Market Stats

By TradingEconomics

Market Cap

-171M

774M

Previous open

5.31

Previous close

2.14

News Sentiment

By Acuity

50%

50%

170 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Iovance Biotherapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

16 Oct 2025, 21:10 UTC

Major Market Movers

Kezar Life Sciences Shares Surge After Break with FDA, Restructuring Plan

16 Oct 2025, 19:03 UTC

Acquisitions, Mergers, Takeovers

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- 2nd Update

16 Oct 2025, 17:58 UTC

Acquisitions, Mergers, Takeovers

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- Update

16 Oct 2025, 17:12 UTC

Earnings

Ray-Ban Maker EssilorLuxottica's Revenue Surges to Quarterly Record -- Update

16 Oct 2025, 17:12 UTC

Acquisitions, Mergers, Takeovers

Canada Signals Limited Concern Over US Government Stakes in Canadian Miners

16 Oct 2025, 16:59 UTC

Acquisitions, Mergers, Takeovers

Airbus's Takeover of Spirit AeroSystems Plants Gets French Antitrust Clearance

16 Oct 2025, 23:44 UTC

Market Talk

Gold Climbs Amid Safe-Haven Demand -- Market Talk

16 Oct 2025, 23:42 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Declines -- Market Talk

16 Oct 2025, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

16 Oct 2025, 22:15 UTC

Earnings

China Tower: Results Supported by Higher Contributions From Energy, Smart Tower Business >0788.HK

16 Oct 2025, 22:15 UTC

Earnings

China Tower 9-Mos Rev CNY74.32B Vs. CNY72.45B >0788.HK

16 Oct 2025, 22:15 UTC

Earnings

China Tower 9-Mos Net CNY8.71B Vs. Net CNY8.15B >0788.HK

16 Oct 2025, 22:02 UTC

Market Talk

Global Equities Roundup: Market Talk

16 Oct 2025, 22:02 UTC

Market Talk

Santos Drifts Into 'Oversold Territory' -- Market Talk

16 Oct 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 Oct 2025, 20:50 UTC

Market Talk
Earnings

Health Care Roundup: Market Talk

16 Oct 2025, 20:23 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 Oct 2025, 20:23 UTC

Market Talk

Recession Risks to Push Canada Toward October Rate Cut -- Market Talk

16 Oct 2025, 20:20 UTC

Earnings

These Stocks Moved the Most Today: TSMC, Salesforce, HPE, F5, United Airlines, Travelers, J.B. Hunt, Praxis Precision, and More -- Barrons.com

16 Oct 2025, 20:08 UTC

Acquisitions, Mergers, Takeovers

Jack in the Box to Sell Del Taco With Big Markdown. The Stock Plunged. -- Barrons.com

16 Oct 2025, 19:37 UTC

Acquisitions, Mergers, Takeovers

Crypto Industry Dives Deeper Into Prediction Markets as Kraken Buys Exchange -- Barrons.com

16 Oct 2025, 19:26 UTC

Earnings

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 Oct 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Falls on Mild Weather, Ample Storage -- Market Talk

16 Oct 2025, 19:23 UTC

Market Talk

Oil Falls As Oversupply Concerns Outweigh India News -- Market Talk

16 Oct 2025, 19:23 UTC

Earnings

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 Oct 2025, 18:35 UTC

Market Talk
Earnings

Charles Schwab Logs Another Quarter of Record Revenues, Earnings -- Market Talk

16 Oct 2025, 18:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 Oct 2025, 18:31 UTC

Market Talk

Global Equities Roundup: Market Talk

16 Oct 2025, 18:31 UTC

Market Talk

Charles Schwab Readies Spot Crypto Trading -- Market Talk

16 Oct 2025, 16:57 UTC

Market Talk

Oil Futures Lose Ground as EIA Reports Crude Stock Build -- Market Talk

Peer Comparison

Price change

Iovance Biotherapeutics Inc Forecast

Price Target

By TipRanks

462.5% upside

12 Months Forecast

Average 12.6 USD  462.5%

High 20 USD

Low 4 USD

Based on 6 Wall Street analysts offering 12 month price targets forIovance Biotherapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

5

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

3.0208 / 3.5Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

170 / 371 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
help-icon Live chat